← Back to headlines
Immunic Closes $200M Private Placement for MS Trials
Immunic has closed a $200 million private placement to fund late-stage multiple sclerosis trials, securing significant capital for its research and development.
17 Feb, 21:33 — 17 Feb, 21:33
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
China sets lower growth target as domestic consumption lags
1m ago
Study finds young people's income development comparable to previous generations, but future outlook weakened
13m ago
Rising fuel costs: SPD General Secretary calls for examination of petrol prices by the Cartel Office
18m ago
China lowers 2026 growth target to 4.5 to 5 per cent, first cut in three years amid mounting headwinds
28m ago